Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 12, 2009Anti-Cancer Drugs

Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities

View Full Paper
Ask AI
Bookmark
Share

Authors

HMHelmout ModjtahediSESharadah Essapen

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Modjtahedi et al. (2009) studied this question.

synapsesocial.com/papers/6a1be25a4ebd09f3dfa92893https://doi.org/10.1097/cad.0b013e3283330590
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer2009 · 3,896 citations
  2. 2Phosphorylated Epidermal Growth Factor Receptor on Tumor-Associated Endothelial Cells Is a Primary Target for Therapy with Tyrosine Kinase Inhibitors2008 · 41 citations
  3. 3Anti–Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?2009 · 64 citations
  4. 4Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer2004 · 5,068 citations